please use calculator method to answer 12. 18 Effects of an appetite suppressant. Subjects with pre-existing cardiovascular symptoms who were receivingsibutramine, an appetite suppressant, were found to beat increased risk of cardiovascular events while taking chatthe drug. The study included 9804 overweight or obesesubjects with preexisting cardiovascular disease and/ortype 2 diabetes. The subjects were randomly assigned tosibutramine (4906 subjects) or a placebo (4898 subjects)in a double-blind fashion. The primary outcome mea-text.stedrveylinesured was the occurrence of any of the following events:nonfatal myocardial infarction or stroke, resuscitationafter cardiac arrest, or cardiovascular death. The primarypro-yes.outcome was observed in 561 subjects in the sibutra-17rge-mine group and 490 subjects in the placebo group."(a) Find the proportion of subjects experiencing theprimary outcome for both the sibutramine andplacebo groups.nceens(b) Can we safely use the large-sample confidence inter-val for comparing the proportions of sibutramineand placebo subjects who experienced the primaryoutcome? Explain.es.re-ngbe

Name: please use calculator method to answer 12. 18 Effects of an appetite s
Uploaded: 2024-03-05T11:52:21.000Z
Channel: Bartleby
Description: please use calculator method to answer 12. 18 Effects of an appetite suppressant. Subjects with pre-existing cardiovascular symptoms who were receivingsibutramine, an appetite suppressant, were found to beat increased risk of cardiovascular events wh

(a) In the survey, out of 4,906 subjects in the sibutramine group of 561 subjects experienced the primary outcome and out of 4,898 subjects in the placebo group of 490 subjects experienced the primary outcome. The proportion of subjects experiencing the primary outcome for the sibutramine group is, psibutramine=5614,906=0.114 Thus, the proportion of subjects experiencing the primary outcome for the sibutramine group is 0.114. The proportion of subjects experiencing the primary outcome for the placebo group is, pplacebo=4904,898=0.100 Thus, the proportion of subjects experiencing the primary outcome for the placebo group is 0.100.(b) The general conditions to use the large-sample confidence interval are given below: Two samples are simple random sample from two distinct populations. The samples are independent. Both populations are normally distributed. The counts of successes and failures are five or more in both the samples. In the survey, the two samples are randomly selected and independent. Moreover, the counts of successes and failures are larger. Hence, the large-sample confidence interval for comparing the proportions of sibutramine and placebo subjects who experienced the primary outcome can be used safely. Let p1 denote the proportions of sibutramine subjects who experienced and primary outcome and p2 denote the proportions of placebo subjects who experienced the primary outcome. Here, compute the 95% confidence interval for the difference between the proportions of sibutramine and placebo subjects who experienced primary outcome by using TI-83 graphing calculator. Confidence interval using TI-83 graphing calculator: Press STAT>TESTS>2-PropZInt. Enter x1 as 561, n1 as 4,906, x2 as 490, n2 as 4,898. C-level: as “0.95”. Select Calculate and press “Enter”. Output: From the output, the 95% confidence interval for the difference between the proportions of sibutramine and placebo subjects who experienced the primary outcome is (0.0021,0.0266). CONCLUDE: There is 95% confident that the difference between the proportions of sibutramine and placebo subjects who experienced the primary outcome lies between 0.21% and 2.66%.